Wire · opportunities
IPS HEART Secures 8th FDA Regulatory Milestone with Rare Pediatric Drug Designation for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 August 2026 · Fusion42 review
IPS HEART has secured Rare Pediatric Drug Designation from the FDA for ISX9-CPC, a therapy targeting cardiomyopathies associated with muscular dystrophies, marking its eighth FDA regulatory milestone. The company plans to file an IND and start clinical trials for its skeletal muscle therapy GIVI-MPCs in 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 6 Aug 2026 and 17 Aug 2026.
◆ ◆ The Wire takeaway
Rare disease biotech founders now have a clear regulatory path for paediatric muscle therapies using iPSC technology. You can engage regulators early and plan trials, as FDA shows willingness to grant expedited designations.
◆ Coverage
2 sources · first reported 6 Aug 2026 · latest 17 Aug 2026
◆ Related on Wire
◆ Topics